The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Updated results from EPCORE NHL-2: epcoritamab plus GemOx in patients with R/R DLBCL
Joshua Brody, MD, Tisch Cancer Institute Mount Sinai, New York, NY, provides a follow-up from the EPCORE NHL-2 trial (NCT04663347), specifically the data from the group of patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), ineligible for autologous stem cell transplantation (autoSCT), who were treated with subcutaneous (SC) epcoritamab in combination with gemcitabine + oxaliplatin (GemOx). Dr Brody expresses his excitement at the high efficacy seen with this treatment regimen compared to epcoritamab or GemOx alone and hopes that this combination therapy will become the standard of care for treating DLBCL in the future. The therapy approach was well tolerated, with cases of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) mainly being low-grade. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: SeaGen, Merck, BMS, Pharmacyclics, ADC Therapeutics, Epizyme, Genentech, Inc., Kite
Consultancy: SeaGen, Merck, BMS, Pharmacyclics, ADC Therapeutics, Epizyme, Genentech, Inc., Kite
